2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the VACCELERATE consortium

BACKGROUND: Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially in aged population. METHODS: We evaluated, with a randomised controlled, adaptive, multicentre phase II study, the safety and immunogenicity of a 3rd vaccination dose (1st booster) in individuals ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmanton-Garcia, Jon, Neuhann, Julia M, Stemler, Jannik, Carcas, Antonio, Frías-Iniesta, Jesús, Bethe, Ullrich, Heringer, Sarah, Tischmann, Lea, Zarrouk, Marouan, Cuepers, Arnd, Koehler, Philipp, Grothe, Jan H, Singh, Samir Kumar, García-León, Alejandro, Loens, Katherine, Lammens, Christine, Koenig, Franz, Yeghiazaryan, Lusine, Posch, Martin, Cornely, Oliver A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677870/
http://dx.doi.org/10.1093/ofid/ofad500.2003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677870/
http://dx.doi.org/10.1093/ofid/ofad500.2003

Ejemplares similares